Researchers in Sri Lanka say China’s Sinopharm vaccine for COVID-19 is highly effective against the delta type, which has become the dominant variant worldwide.

According to a study conducted at the University of Sri Jayawardenepur, after receiving two doses of Sinopharm vaccine, 95% of study participants developed antibodies similar to those of a person infected with the COVID-19 virus.

The two doses of Sinopharm also produced neutralizing antibodies in 81.25% of study participants, and these antibody levels were also similar to those found in humans after recovering from natural COVID-19 infection.

Among the 20–40 age group, 98% of the study participants developed antibodies against the delta variation, while in the over 60 age group, 93% developed antibodies against the delta variation.

Professor Neleka Malawi, Chair of the Department of Immunology and Molecular Medicine, Sri Jayawardenepur University, this is the first study of its kind because the researchers looked at every possible aspect of the immune system with the Sinopharm COVID-19 vaccine.

The following two tabs change content below.


Please enter your comment!
Please enter your name here